Guidelines of the Polish Society of Arterial Hypertension as the newest document of diagnostics and treatment of hypertension. Place of the new hypotensive drugs on an example of zofenopril Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
arterial hypertension, guidelines, zofenopril
Main Article Content
Abstract
Hypertension is not only one of the diseases most common in the general population, but also one of the main risk factors for cardiovascular disease. Due to the large burden of hypertension in the general population, it attracts continous attention of both clinicians as well as scientific societies. In May 2015 the latest recommendations of Polish Society of Arterial Hypertension (PTNT) were issued. They systematize knowledge about the diagnostics and treatment of the disease. In the document particular attention was paid to pharmacotherapy, also with a use of modern molecules such as zofenopril, which place in the PTNT guidelines is discussed in this summary.
Article Details
How to Cite
Płatek , A. E., & Szymański , F. M. (2015). Guidelines of the Polish Society of Arterial Hypertension as the newest document of diagnostics and treatment of hypertension. Place of the new hypotensive drugs on an example of zofenopril. Medycyna Faktow (J EBM), 8(2(27), 81-86. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2316
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zdrojewski T., Rutkowski M., Bandosz P. et al.: Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71: 381-392.
2. Zdrojewski T., Bandosz P., Rutkowski M. et al.: Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce – wyniki badania NATPOL 2011. Nadciśnienie Tętnicze 2014; 18: 116-117.
3. Bosomworth N.J.: Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can. Fam. Physician. 2013; 59: 1169-1180.
4. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
6. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28(suppl. 2): S115-S130.
7. Subissi A., Evangelista S., Giachetti A.: Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1989; 17: 115-133.
8. Borghi C., Bacchelli S., Degli Esposti D.: Long-term clinical experience with zofenopril. Expert Rev. Cardiovasc. Ther. 2012; 10(8): 973-982.
9. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202-2212.
10. Latini R., Tognoni G., Maggioni A.P. et al.; Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group: Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J. Am. Coll. Cardiol. 2000; 35: 1801-1807.
11. Borghi C., Ambrosioni E., Novo S. et al.: SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallelgroup, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35: 416-423.
2. Zdrojewski T., Bandosz P., Rutkowski M. et al.: Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce – wyniki badania NATPOL 2011. Nadciśnienie Tętnicze 2014; 18: 116-117.
3. Bosomworth N.J.: Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can. Fam. Physician. 2013; 59: 1169-1180.
4. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
6. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28(suppl. 2): S115-S130.
7. Subissi A., Evangelista S., Giachetti A.: Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1989; 17: 115-133.
8. Borghi C., Bacchelli S., Degli Esposti D.: Long-term clinical experience with zofenopril. Expert Rev. Cardiovasc. Ther. 2012; 10(8): 973-982.
9. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202-2212.
10. Latini R., Tognoni G., Maggioni A.P. et al.; Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group: Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J. Am. Coll. Cardiol. 2000; 35: 1801-1807.
11. Borghi C., Ambrosioni E., Novo S. et al.: SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallelgroup, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35: 416-423.